Shield Therapeutics plc (STX)
LSE
Closed
Oct 29, 2026
Day's Range
5.3052 wk Range
3.70Overview - STX - Shield Therapeutics plc
Key Statistics
Valuation
Enterprise Value
56.16M
P/E (Trailing)
-268.24
P/E (Forward)
7.26
PEG Ratio
7.26
Price / Sales (TTM)
0.99
EV / EBITDA
-16.90
Profitability
Profit Margin
-17.69%
Operating Margin
0.68%
Return on Assets
-4.37%
Return on Equity
117.09%
Ownership
Shares Outstanding
1.06B
Float
413.37M
Held by Insiders
61.50%
Held by Institutions
3.32%
Price stats
Beta
1.73
50-Day Avg
5.25
200-Day Avg
7.01
Dividends
Payout Ratio
0.00%
Analyst Consensus
6 analysts
Market Cap - STX - Shield Therapeutics plc
Peers - STX - Shield Therapeutics plc
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on LSE.
- STXLSEShield Therapeutics plc5.85BMarket Cap-26.75%52-week change-268.25P/E (Trailing)-17.69%Profit Margin
- HLNLSEHaleon plc2.81TMarket Cap-11.99%52-week change17.91P/E (Trailing)14.55%Profit Margin
- 0QFPLSEGedeon Richter Plc.1.74TMarket Cap+0.00%52-week change7.34P/E (Trailing)19.72%Profit Margin
- HIKLSEHikma Pharmaceuticals PLC343.98BMarket Cap-7.52%52-week change12.69P/E (Trailing)11.31%Profit Margin
- ROSELSERosebank Industries plc308.38BMarket Cap-7.69%52-week change—P/E (Trailing)-4.92%Profit Margin
- HCMLSEHUTCHMED (China) Limited182.22BMarket Cap-5.29%52-week change207.00P/E (Trailing)3.25%Profit Margin
- 0MTDLSESwedish Orphan Biovitrum AB163.09BMarket Cap+28.37%52-week change46.33P/E (Trailing)15.54%Profit Margin
Profile Summary - STX - Shield Therapeutics plc
About
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company dedicated to developing and commercializing late-stage, hospital-focused pharmaceuticals, primarily addressing iron deficiency in adult patients. Its flagship product, Accrufer® (also known as Feraccru® in certain regions), is an…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
